BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25212680)

  • 21. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
    Smith BN; Savona M; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.
    Gerds AT
    Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Linder K; Iragavarapu C; Liu D
    Biomark Res; 2017; 5():33. PubMed ID: 29225884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
    Orazi A; Germing U
    Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peculiarities in the Diagnosis Approach of MDS /MPN-U Patients.
    Triantafyllidis I; Ciobanu A; Stanca O; Draghici C; Angelescu S; Tapelea E
    Maedica (Bucur); 2012 Jun; 7(2):173-6. PubMed ID: 23401728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
    Hochman MJ; Savani BN; Jain T
    EJHaem; 2021 Aug; 2(3):607-615. PubMed ID: 35844680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
    Fontana D; Elli EM; Pagni F; Piazza R
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
    Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
    Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.
    Li B; Gale RP; Xiao Z
    J Hematol Oncol; 2014 Dec; 7():93. PubMed ID: 25498990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
    Gerke MB; Christodoulou I; Karantanos T
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
    Harada H
    Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
    [No Abstract]   [Full Text] [Related]  

  • 32. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
    Michaux JL; Martiat P
    Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
    Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
    Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
    Thota S; Gerds AT
    Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic complexity of chronic myelomonocytic leukemia.
    Patel AB; Deininger MW
    Leuk Lymphoma; 2021 May; 62(5):1031-1045. PubMed ID: 33337259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
    Li Y; Beck RC; Moore EM
    Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.